ReviewAdvances in parasitology2021
Clinical management of Plasmodium knowlesi malaria.
Review in Advances in parasitology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Plasmodium knowlesi Malaria in Persons Returning to Israel from Thailand, 2023.Emerging infectious diseases · 2025Article
- Plasmodium knowlesi Infection Is Associated With Elevated Circulating Biomarkers of Brain Injury and Endothelial Activation.The Journal of infectious diseases · 2025Article
- Engineering scutellarin biosynthesis in Artemisia annua.Plant cell reports · 2025Article
- Genomic epidemiology of Plasmodium knowlesi reveals putative genetic drivers of adaptation in Malaysia.PLoS neglected tropical diseases · 2025Article
- Severe knowlesi malaria with acute neurocognitive impairment: A case report.IJID regions · 2025Article
- Research Progress on Sesquiterpene Compounds from Artabotrys Plants of Annonaceae.Molecules (Basel, Switzerland) · 2024Review
- Updating estimates of Plasmodium knowlesi malaria risk in response to changing land use patterns across Southeast Asia.PLoS neglected tropical diseases · 2024Review
- Review
- Updating estimates ofmedRxiv : the preprint server for health sciences · 2023Article
- Plasmodium cynomolgi in humans: current knowledge and future directions of an emerging zoonotic malaria parasite.Infection · 2023Review
- Quantification of parasite clearance in Plasmodium knowlesi infections.Malaria journal · 2023Article
- Severe malaria.Malaria journal · 2022Review
- Semi-Synthetic Analogues of Cryptolepine as a Potential Source of Sustainable Drugs for the Treatment of Malaria, Human African Trypanosomiasis, and Cancer.Frontiers in pharmacology · 2022Article
- Diagnostic accuracy and limit of detection of ten malaria parasite lactate dehydrogenase-based rapid tests forFrontiers in cellular and infection microbiology · 2022Article
- Knowlesi malaria: Human risk factors, clinical spectrum, and pathophysiology.Advances in parasitology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
The zoonotic parasite Plasmodium knowlesi has emerged as an important cause of human malaria in parts of Southeast Asia. The parasite is indistinguishable by microscopy from the more benign P. malariae, but can result in high parasitaemias with multiorgan failure, and deaths have been reported. Recognition of severe knowlesi malaria, and prompt initiation of effective therapy is therefore essential to prevent adverse outcomes. Here we review all studies reporting treatment of uncomplicated and severe knowlesi malaria. We report that although chloroquine is effective for the treatment of uncomplicated knowlesi malaria, artemisinin combination treatment is associated with faster parasite clearance times and lower rates of anaemia during follow-up, and should be considered the treatment of choice, particularly given the risk of administering chloroquine to drug-resistant P. vivax or P. falciparum misdiagnosed as P. knowlesi malaria in co-endemic areas. For severe knowlesi malaria, intravenous artesunate has been shown to be highly effective and associated with reduced case-fatality rates, and should be commenced without delay. Regular paracetamol may also be considered for patients with severe knowlesi malaria or for those with acute kidney injury, to attenuate the renal damage resulting from haemolysis-induced lipid peroxidation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.